Form 4: BRUKER CFO Granted Equity Awards

Bruker Corporation's CFO, Gerald N. Herman, was granted 25,844 Restricted Stock Units and 24,430 stock options, effective August 15, 2025, as part of executive compensation.

Summary

• Gerald N. Herman, Executive Vice President and CFO of Bruker Corporation (BRKR), was granted equity awards.
• On August 15, 2025, Mr. Herman acquired 25,844 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0.
• These RSUs vest in equal installments on the first, second, third, and fourth anniversaries of the August 15, 2025 grant date.
• Following this transaction, Mr. Herman beneficially owns 102,583 shares of Common Stock.
• Additionally, on August 15, 2025, Mr. Herman acquired 24,430 Stock Options with an exercise price of $36.872.
• These Stock Options also vest in equal installments on the first, second, third, and fourth anniversaries of the August 15, 2025 grant date.
• The Stock Options become exercisable on August 15, 2026, and expire on August 15, 2035.
• Following this transaction, Mr. Herman beneficially owns 24,430 Stock Options.

Sentiment

Score: 7

Explanation: The filing reports a routine executive compensation grant, which is a positive for aligning management incentives with shareholder interests, but it does not introduce new information that would significantly alter the company's fundamental outlook.

Positives

• The equity grants align the financial interests of the CFO with those of the shareholders, incentivizing long-term performance and value creation.
• The vesting schedule over four years encourages executive retention and sustained commitment to the company's strategic goals.

Negatives

• The future conversion of RSUs and exercise of stock options could lead to a minor dilutive effect on existing shares, although this is a standard aspect of equity compensation.

Future Outlook

The vesting schedules for both the Restricted Stock Units and Stock Options extend over four years from the grant date, indicating a long-term incentive structure for the CFO.

Industry Context

The grant of equity awards to senior executives is a common and widely accepted practice across various industries, including the life sciences and analytical instrumentation sector where Bruker operates. This compensation structure is designed to align management's long-term interests with shareholder value creation.

Comparison to Industry Standards

• The structure of granting Restricted Stock Units (RSUs) and stock options with multi-year vesting schedules is a standard component of executive compensation packages in publicly traded companies, comparable to practices at peers like Thermo Fisher Scientific (TMO) or Danaher Corporation (DHR).
• The specific number of shares and options granted would typically be benchmarked against compensation for similar roles at companies of comparable size and industry within Bruker's peer group, though specific peer comparisons are not detailed in this filing.

Related Party Transactions

• The grant of equity awards to Gerald N. Herman, the Executive Vice President and CFO, constitutes a related party transaction as it involves compensation to a key management personnel.

Stakeholder Impact

• Shareholders: The equity grants are intended to align the CFO's interests with shareholder value creation, potentially leading to improved long-term performance.
• Employees: This filing reflects standard executive compensation practices, which can influence overall company compensation philosophy and employee morale.

Next Steps

• The Restricted Stock Units and Stock Options will vest in equal installments on the first, second, third, and fourth anniversaries of the August 15, 2025 grant date.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to a key executive, which is a standard practice for aligning management incentives with shareholder value. It does not provide new information that would significantly alter the investment thesis for Bruker Corporation, thus a 'hold' recommendation is appropriate.

Keywords

Bruker, BRKR, SEC Form 4, Executive Compensation, Stock Options, Restricted Stock Units, Insider Transaction, Gerald N. Herman, CFO